Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2137255 | 0.88 | NPSR1 (0.43) | HSD17B10NPSR1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL2724717 | 0.85 | NPC1 (0.37) | ALDH1A1NPC1AADAT | |
| SCHEMBL2708567 | 0.81 | DPP4 (0.42) | NPC1AADAT | |
| SCHEMBL2141159 | 0.81 | CYP1A2 (0.34) | HSD17B10NPSR1LMNAL3MBTL1MEN1 | |
| SCHEMBL2708134 | 0.80 | MEN1 (0.40) | NPSR1LMNAALDH1A1MAPTMEN1 | |
| SCHEMBL2135766 | 0.79 | L3MBTL1 (0.45) | NPSR1LMNAL3MBTL1ALDH1A1MAPT | |
| SCHEMBL2135903 | 0.79 | HTT (0.46) | NPSR1LMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL2139521 | 0.78 | L3MBTL1 (0.44) | NPSR1LMNAL3MBTL1ALDH1A1MAPT | |
| SCHEMBL2136182 | 0.78 | L3MBTL1 (0.44) | NPSR1LMNAL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL657227 | 0.78 | NPC1 (0.43) | HSD17B10NPSR1LMNAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2447265-A1 | NOVEL THIOPHENE CARBOXAMIDE DERIVATIVE AND MEDICINAL USE OF SAME | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | GCK, GCKR, HK2 | HSD17B10 1447/4885NPSR1 2520/4885LMNA 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.